Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, Eid E, McIntyre JK, Bailey I, Furukawa LK, Gorell ES, Harris N, Khosla RK, Peter Lorenz H, Lu Y, Nazaroff J, Grachev ID, Moore AJ.
Tang JY, et al.
Lancet. 2025 Jun 23:S0140-6736(25)00778-0. doi: 10.1016/S0140-6736(25)00778-0. Online ahead of print.
Lancet. 2025.
PMID: 40570869